Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle ; volume:9 ; number:1 ; day:23 ; month:3 ; year:2018 ; pages:1 ; date:12.2018
Nature Communications ; 9, Heft 1 (23.3.2018), 1, 12.2018
- Klassifikation
-
Allgemeines, Wissenschaft
- Urheber
-
Novak, James S.
- Beteiligte Personen und Organisationen
-
Hogarth, Marshall W.
Boehler, Jessica F.
Nearing, Marie
Vila, Maria C.
Heredia, Raul
Fiorillo, Alyson A.
Zhang, Aiping
Hathout, Yetrib
Hoffman, Eric P.
Jaiswal, Jyoti K.
Nagaraju, Kanneboyina
Cirak, Sebahattin
Partridge, Terence A.
SpringerLink (Online service)
- DOI
-
10.1038/s41467-018-03709-8
- URN
-
urn:nbn:de:1111-201805271400
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Novak, James S.
- Hogarth, Marshall W.
- Boehler, Jessica F.
- Nearing, Marie
- Vila, Maria C.
- Heredia, Raul
- Fiorillo, Alyson A.
- Zhang, Aiping
- Hathout, Yetrib
- Hoffman, Eric P.
- Jaiswal, Jyoti K.
- Nagaraju, Kanneboyina
- Cirak, Sebahattin
- Partridge, Terence A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Antisense Oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Wnt7a is required for regeneration of dystrophic skeletal muscle
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Antisense Oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Wnt7a is required for regeneration of dystrophic skeletal muscle
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
Antisense Oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Splicing modulation via antisense oligonucleotides in recessive dystrophic epidermolysis bullosa
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Wnt7a is required for regeneration of dystrophic skeletal muscle
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity